> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Latest Federal Register Notices
- URL: https://www.fdaweb.com/latest-federal-register-notices-190/
- Published: 2018-08-12T12:00:00.000Z
- Updated: 2026-09-15T00:25:11.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5142097

[**Workshop on Human Skin Safety Testing for Topicals**](https://www.fdaweb.com/workshop-on-human-skin-safety-testing-for-topicals/)  
*Federal Register* notice: FDA announces a 9/10 public workshop entitled “Human Dermal (Skin) Safety Testing for Topical Drug Products: Regulatory Utility and Evaluation.” 08/10/2018

[**FDA Proposes New Drug Promotion Study on Disclosures**](https://www.fdaweb.com/fda-proposes-new-drug-promotion-study-on-disclosures/)  
*Federal Register* notice: FDA submits to OMB a new information collection study entitled “Disclosures in Professional and Consumer Prescription Drug Promotion” (OMB Control Number 0910-New). 08/10/2018

[**Guide on Drug Dissolution Testing**](https://www.fdaweb.com/guide-on-drug-dissolution-testing/)  
*Federal Register* notice: FDA makes available a guidance entitled “Dissolution Testing and Acceptance Criteria for Immediate-Release Solid Oral Dosage Form Drug Products Containing High Solubility Drug Substances.” 08/09/2018

[**Prolixin Not Withdrawn Due to Safety/Efficacy: FDA**](https://www.fdaweb.com/prolixin-not-withdrawn-due-to-safety-efficacy-fda/)  
*Federal Register* notice: FDA determines that Prolixin (fluphenazine hydrochloride) tablets, 1 mg (mg), 2.5 mg, 5 mg, and 10 mg, were not withdrawn from sale for reasons of safety or effectiveness. 08/09/2018

[**4 NDA Approvals Withdrawn by FDA**](https://www.fdaweb.com/4-nda-approvals-withdrawn-by-fda/)  
*Federal Register* notice: FDA withdraws approval of four NDAs from multiple applicants after they told the agency that the products were no longer marketed. 08/08/2018

[**27 ANDAs Being Withdrawn by FDA**](https://www.fdaweb.com/27-andas-being-withdrawn-by-fda/)  
*Federal Register* notice: FDA withdraws 27 ANDAs from multiple applicants after the application holders told the agency that the drug products were no longer marketed. 08/08/2018

[**Info Collection Extension for Device Reclassification Petitions**](https://www.fdaweb.com/info-collection-extension-for-device-reclassification-petitions/)  
*Federal Register* notice: FDA submits to OMB an information collection extension for “Reclassification Petitions for Medical Devices” (OMB Control Number 0910-0138). 08/07/2018

[**Draft Guide on Opioid Use Disorder Drug Endpoints**](https://www.fdaweb.com/draft-guide-on-opioid-use-disorder-drug-endpoints/)  
*Federal Register* notice: FDA makes available a draft guidance entitled “Opioid Use Disorder: Endpoints for Demonstrating Effectiveness of Drugs for Medication-Assisted Treatment.” 08/07/2018